

Exacerbation Reduction Over Three Years with Beclometasone/Formoterol/Glycopyrronium in Asthma: Real-World Evidence from the TriMaximize Study

Prof. Frederik Trinkmann




Scan to download the presentation

F. Trinkmann¹, V. Bogoevska², R.E.K. Russell³, C. Suppli Ulrik⁴, W. Pohl⁵, V. Plaza⁶, A. Bourdin⁷, M. Kupczyk⁸, F. Braido⁹, A. Hahn², C. Fritz², V. Grickschat², C. Gessner¹⁰.

¹Department of Pneumology and Critical Care, Translational Lung Research Center Heidelberg, Heidelberg, ²Chiesi GmbH, Hamburg, ³King's College London, London, ⁴Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Hvidovre, ⁵Karl Landsteiner Institute for Clinical and Experimental Pneumology, Clinic Hietzing, Vienna, ⁶Hospital de la Santa Creu i Sant Pau, Barcelona, ⁷Hôpital Arnaud de Villeneuve, University of Montpellier, France, ⁸Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz; ⁹Università degli Studi di Genova - Ospedale San Martino, Genova, ¹⁰Specialized Practice for Pulmonary Medicine, Leipzig.

Study overview



Selected baseline characteristics

Age - 57.6 years

Female - 62.8%

Never smoker - 52.2%

Current smoker - 17.9%

Former smoker - 29.8%

GINA Step 4 - 76.3%

GINA Step 5 - 23.7%

Comorbidities - 85.3%

- COPD - 22.4%


Prior treatment:

- ICS/LABA (fixed or free) - 72.7%
- ICS/LABA/LAMA (fixed or free) - 27.3%



Scan to download the presentation

Decrease in moderate and severe exacerbations with BDP/FF/G therapy




The proportion of patients experiencing at least one moderate or severe exacerbation decreased after 3 years of follow-up.



Scan to download the presentation

Moderate exacerbations were defined as ≥ 2 consecutive days of increased rescue bronchodilator use (≥ 4 puffs/day), and severe as those requiring systemic corticosteroids for ≥ 3 days or resulting in emergency care or hospitalization.

Severity of exacerbations at baseline under previous treatment and after three years of treatment with BDP/FF/G




The proportion of patients experiencing moderate or severe exacerbations decreased after 3 years of follow up – suggesting improved disease stability.



Scan to download the presentation

Moderate exacerbations were defined as ≥ 2 consecutive days of increased rescue bronchodilator use (≥ 4 puffs/day), and severe as those requiring systemic corticosteroids for ≥ 3 days or resulting in emergency care or hospitalization.

Reduction in the mean rate of moderate and severe exacerbations



Moderate exacerbations were defined as ≥2 consecutive days of increased rescue bronchodilator use (≥4 puffs/day), and severe as those requiring systemic corticosteroids for ≥3 days or resulting in emergency care or hospitalization.




Exacerbation rate decreased by 1.5 points after three years of follow-up in patients with moderate and severe asthma.



Scan to download the presentation

Conclusions:



Significant and sustained reduction in exacerbations was observed over a three-year period in patients with moderate to severe asthma treated with BDP/FF/G in this prospective real-world study.



Scan to download the presentation